MRNA Moderna: mrna-1403 did not meet statistical criteria for early success at phase 3 interim analysis, preparing to enroll additional coho

MRNA Q2 revs $100M misses the $103M estimate, hit by weaker-than-expected sales of its COVID-19 shot, ahead of an upcoming regulatory decision for its experimental flu vaccine; anticipates potential approval of Moderna’s 5th product with August 5th PDUFA date for Mflusiva; said MRNA-1403 did not meet statistical criteria for early success at phase 3 interim analysis, preparing to enroll additional cohort; said expects about 55% of its second half 2026 revenue to be recognized in the third quarter; shares -4.5% premarket